FLAGSHIP ANNUAL REPORT

The State of **The Indian Body**

Annual Report 2026

A synthesis of every meaningful clinical study — Indian or applicable to Indians — released in the past twelve months. The Lancet, Nature Medicine, Indian Journal of Medical Research, ICMR, NCRP, AQLI — read for you. One document. Citation-grade.

ICMR-INDIAB 2023 · GBD STUDY 2019–21 · AQLI 2025 · NCRP 2025 · LANCET PLAN · JAMA / JACC ASIA

101M	1.67M	5.3yr	50%
INDIANS WITH DIABETES	ANNUAL POLLUTION DEATHS	LIFE LOST TO AIR POLLUTION	INDIAN MI… AGE 50

CONTENTS

The Annual Report, 2026

EXECUTIVE SUMMARY

What We Found — And Why It Cannot Be Ignored

India is in the middle of **four simultaneous epidemics**: a metabolic epidemic (diabetes, insulin resistance, obesity), a cardiovascular epidemic (premature heart disease in the young workforce), a cancer epidemic (rising incidence of breast and lung while preventable cancers persist), and an environmental epidemic (particulate air pollution claiming 1.67 million lives annually).

These epidemics are not independent. **Insulin resistance drives cardiovascular risk. Air pollution drives insulin resistance. Poverty drives all four.** The Indian body is navigating an obstacle course that no other population has navigated at this speed and scale simultaneously.

The landmark ICMR-INDIAB study — the most comprehensive diabetes survey ever conducted in India — confirmed **101 million diabetics and 136 million in prediabetes**. These numbers far exceeded all prior estimates. They mean that roughly 1 in 4 Indian adults above 30 is on a metabolic spectrum that will, without intervention, result in organ damage.

The cardiovascular data is equally alarming. **Half of all heart attacks in Indian men occur under 50. A quarter occur under 40.** The Indian Heart Association's data, corroborated by the Lancet, confirms that Indians develop CAD 5–10 years earlier than Western populations — at lower LDL-C values, at lower BMIs, driven by genetic particle burden and metabolic risk that conventional screening misses.

Against this backdrop, Kerala and parts of the Northeast offer a counter-narrative: what happens when literacy, primary healthcare, women's empowerment, and community cohesion are treated as health investments. Kerala's life expectancy of **76 years rivals developed nations** — achieved at a fraction of their per-capita income. The model is replicable. The question is whether India will choose to replicate it.

This report — the first of what will be an annual publication — synthesises the best available clinical evidence on each front. Every number is cited. Every claim is linked. It is the document we wished had existed for us.

101M

DIABETICS IN INDIA (ICMR-INDIAB, LANCET 2023)

Plus 136 million in prediabetes. Together: 237 million on the glycaemic spectrum.

315M

INDIANS WITH HYPERTENSION (ICMR-INDIAB 2023)

Seven in eight hypertensive adults remain uncontrolled.

1.67M

DEATHS/YR FROM AIR POLLUTION (GBD 2019, LANCET PH)

17.8% of all Indian deaths. $36.8 billion economic cost.

53 yr

MEAN AGE OF FIRST MI IN INDIA (VS. 63 IN THE WEST)

A decade of productive life lost. Premature CAD is a national crisis.

29.8M

CANCER DALYS PROJECTED FOR INDIA IN 2025 (NCRP/ICMR)

Lung, breast, mouth, oesophagus, cervix are the leading sites.

8.2 yr

LIFE LOST TO POLLUTION IN DELHI (AQLI 2025)

544 million in the IGP breathe the world's most polluted air.

I CHAPTER

ICMR-INDIAB · LANCET DIABETES & ENDOCRINOLOGY · 2023

The State of the Average Indian Body

Metabolic disease at scale — hypertension, obesity, hypercholesterolaemia, and the regional divide

The most comprehensive snapshot of the Indian body ever assembled was published in June 2023 in *The Lancet Diabetes & Endocrinology*. The ICMR-INDIAB study — India Diabetes, funded by the Indian Council of Medical Research, conducted by the Madras Diabetes Research Foundation across 31 states and Union Territories, with 124,000 participants — confirmed numbers that shocked the medical community: India is not a developing country approaching a metabolic crisis. It is already inside one.

101M	136M	315M	254M
PERSONS WITH DIABETES IN INDIA, 2021	IN PREDIABETES	WITH HYPERTENSION	WITH GENERALISED OBESITY

351M	213M
WITH ABDOMINAL	WITH

OBESITY HYPERCHOLESTEROLAEMIA

These are not projections. These are measured prevalences from a nationally representative stratified survey, projected to the 2021 population. The total — approximately **1.37 billion people, of whom 237 million are on the glycaemic spectrum, 315 million are hypertensive, and 351 million carry abdominal obesity** — represents a metabolic emergency with no historical precedent in a single country.

THE URBAN-RURAL GRADIENT

India's metabolic crisis is not uniform. The ICMR-INDIAB data reveals a steep urban-rural gradient: diabetes prevalence is consistently higher in urban areas across all states. Tamil Nadu exemplifies this: 10.4% overall prevalence, with urban rates substantially exceeding rural. Chandigarh, the most urbanised Union Territory in the study, recorded 13.6% diabetes prevalence. Jharkhand, predominantly rural, showed 5.3%.

The gradient is tightening. Urbanisation and dietary transition are carrying metabolic risk into previously protected rural populations at speed. **The expectation that rural India is metabolically safe is increasingly false.** A 2023 comprehensive review noted that up to one third of urban Indians in major cities already have metabolic syndrome. Rural India is following, with a lag of roughly one generation.

▲ DIABETES PREVALENCE BY STATE CATEGORY — ICMR-INDIAB (INDICATIVE)

Chandigarh (Urban UT)	13.6%
Tamil Nadu	10.4%
Jammu (Urban)	~26.5%*
Jammu (Rural)	14.5%

Jharkhand (Rural)	5.3%

*Urban Jammu is an outlier. Source: ICMR-INDIAB multi-phase data. aqli.epic.uchicago.edu

THE HYPERTENSION BLIND SPOT

Of 315 million hypertensive Indians, the majority remain undetected or uncontrolled. A 2023 review cited in the Lancet context noted that **seven in eight hypertensive adults in India were out of control** — meaning their blood pressure was not at target despite being known to be elevated. Hypertension is the leading proximate cause of stroke in India, which carries an age-standardised mortality rate significantly higher than the global average for middle-income countries.

The silent nature of hypertension — producing no symptoms for years while destroying renal vasculature, causing left ventricular hypertrophy, and laying the inflammatory groundwork for CAD — makes the detection gap a compounding disaster. An Indian who is diagnosed hypertensive at 45 has likely been hypertensive since 38. An Indian who never checks their blood pressure may not discover it until their first stroke. → Lancet Diabetes & Endocrinology 2023

> 📋 PRIMARY SOURCE – ICMR-INDIAB-17, LANCET DIABETES & ENDOCRINOLOGY, JUNE 2023
>
> **Study design:** Cross-sectional population-based survey, stratified multistage sampling. 31 states + UTs + NCT Delhi. n=124,000+. Ages 20+. Urban and rural areas.
>
> **Key projections for 2021:** 101 million diabetics · 136 million prediabetics · 315 million hypertensive · 254 million generalised obese · 351 million abdominally obese · 213 million hypercholesterolaemia · 185 million high LDL-C.
>
> **Authors:** Anjana RM, Deepa M, Pradeepa R et al., ICMR–INDIAB Collaborative Study Group. Madras Diabetes Research Foundation.

ABDOMINAL OBESITY: THE SILENT ACCELERANT

The figure of 351 million abdominally obese Indians — larger than the entire population of the United States — is clinically crucial because abdominal (visceral) obesity is a stronger predictor of metabolic disease than generalised obesity in South Asians. The "thin-fat Indian phenotype" means that many Indians who appear lean by BMI carry visceral fat depots equivalent to obese Westerners. Standard BMI-based

screening misses them. Waist circumference, waist-to-height ratio, and abdominal imaging are required to see the true picture. These are rarely measured in routine Indian clinical encounters.

▲ NATIONAL METABOLIC BURDEN (ICMR-INDIAB, 2021)

Diabetes	101M
Prediabetes	136M
Hypertension	315M
Abdominal Obesity	351M
Hypercholesterolaemia	213M

◆ KEY CONTEXT

40% of identified diabetics in Jammu were previously undiagnosed — typical of the national detection gap.

India ranked **2nd globally** in absolute number of adults with diabetes (IDF 2021 estimates).

Urban diabetes rate is **consistently double** the rural rate across all states studied.

Metabolic India

Diabetes, insulin resistance, the thin-fat phenotype, and the decade-early warning that conventional medicine misses

India's diabetes story is not merely one of large numbers. It is a story of biological phenotype, of a population whose metabolic machinery is configured differently — not defectively, but in ways that evolved in a resource-scarce environment and are now catastrophically mismatched with caloric abundance. Understanding *why* Indians develop diabetes faster, at lower weights, and at younger ages than Western populations is essential to understanding what interventions can actually work.

THE THIN-FAT INDIAN — A BIOLOGICAL REALITY

The phrase "thin-fat Indian" was coined to describe a consistent and disturbing clinical observation: Indians at BMIs that Western medicine classifies as "healthy" or "overweight" carry visceral, hepatic, and pancreatic fat depots equivalent to those seen in obese Western patients. This is not a metaphor. It is measurable by MRI, confirmed in multiple cohort studies, and mechanistically explained by genetic differences in regional fat distribution — specifically, a reduced capacity to store fat safely in subcutaneous depots, which forces overflow into visceral and ectopic sites where it drives insulin resistance and β-cell dysfunction.

> ⚠ CRITICAL FINDING – ASIAN INDIAN PREDIABETES STUDY (NCT04507685)
>
> Compared to other races, **Indians have higher insulin resistance, poorer pancreatic function, and a more rapid decline in β-cell function** — with increased ectopic fat deposition in the liver and pancreas at BMIs that do not trigger concern in Western screening models. A 53-SNP insulin resistance genetic risk score has been identified that predicts metabolic outcomes in Indians independent of BMI. → ClinicalTrials.gov NCT04507685

THE FASTING INSULIN REVELATION

A landmark Mumbai study screened 1,313 young adults aged 16–25 as part of a diabetes prevention trial. Only 4.2% met ADA prediabetes criteria by HbA1c. But **30.5% had hyperinsulinaemia despite perfectly normal blood glucose and HbA1c** — their pancreases were already working overtime to maintain normal sugar levels. Among those with HbA1c below 5.7% (classified as "normal"), 10.5% had elevated fasting insulin above 15 mIU/L, and 39.4% had elevated 2-hour stimulated insulin above 80 mIU/L.

These young people — studying, exercising, eating "normally" by Indian standards — are running a metabolic deficit that will manifest as prediabetes in their thirties and diabetes in their forties. Fasting insulin, which costs approximately ₹250–₹400 at any accredited Indian lab, would catch them. It is almost never ordered. → Frontiers in Clinical Diabetes, 2023 · PMC10186728

> 📋 EARLY SCREENING EVIDENCE — PMC (KERALA), 2025
>
> Among 2,540 community-dwelling non-obese Indians aged 18–30 screened across Kerala using OGTT, FPG, and HbA1c: **diabetes detected in 2.0% and prediabetes in 19.5%** — nearly 1 in 5 young, non-obese Indians already in prediabetes. The ADA recommends screening at age 35; this data argues for screening from 20 onward in Indian populations. → PMC12274043

THE 14-YEAR TRAJECTORY

A 14-year prospective cohort study of Dutch South Asians (Rotterdam cohort, 270 participants with 14-year follow-up published 2025) found that baseline metabolic syndrome predicted incident T2D with an adjusted odds ratio of 2.6 (95% CI 1.2–5.7). Crucially, **standard risk scores validated in White European populations systematically underestimated T2D incidence in South Asians** — confirming that ethnic-specific risk thresholds and phenotyping are necessary, not optional.

"Indians develop diabetes nearly a decade earlier than Western

populations, at lower BMIs, through a distinct mechanism of ectopic fat accumulation and accelerated β-cell failure that conventional screening tools are not designed to detect."

– SYNTHESIS OF ICMR-INDIAB, ASIAN INDIAN PREDIABETES STUDY, AND FRONTIERS CLINICAL DIABETES RESEARCH 2023–2025

▲ THE METABOLIC SEQUENCE

Step 1: Visceral + ectopic fat at normal BMI → insulin resistance begins (detectable by HOMA-IR, fasting insulin)

Step 2: Pancreas compensates → hyperinsulinaemia (HbA1c still normal)

Step 3: β-cell fatigue → HbA1c rises → prediabetes diagnosis (typically 8–12 years after Step 1)

Step 4: β-cell failure → Type 2 Diabetes (often 10–15 years after Step 1)

Fasting insulin catches Step 2. Standard panels only catch Step 3.

◆ BY THE NUMBERS

19.5% of young non-obese Indians already in prediabetes	Kerala 2025
30.5% of 16–25 yr olds hyperinsulinaemic despite normal HbA1c	Mumbai 2023
India will have 2nd most diabetics globally by 2045	IDF

III CHAPTER

LANCET REGIONAL HEALTH · PMC · NCRB · INDIAN HEART ASSOCIATION

The Heart at Forty

Half of Indian heart attacks happen before 50. A quarter before 40. The biology of why — and what the data demands

---

The most reliable way to understand how severe India's cardiovascular crisis is, is this single statistic from the Indian Heart Association: **half of all heart attacks in Indian men occur under the age of 50. A quarter occur under 40.** In the West, the mean age of first MI is approximately 64 years. In India, it is 53. That is not a difference of degree. It is a decade of productive life, of parenting, of economic contribution, subtracted by a disease that could have been caught — and largely prevented — years earlier.

53 yr	50%	25%	+12.5%
MEAN AGE OF FIRST MI IN INDIA	INDIAN MALE MIS UNDER AGE 50	INDIAN MIS UNDER AGE 40	RISE IN MI DEATHS IN 2022 ALONE (NCRB)

5–10yr
EARLIER ONSET VS WESTERN POPULATIONS

THE PARADOX: LOW LDL, HIGH RISK

Indian cardiovascular patients present a diagnostic paradox that has puzzled Western-trained cardiologists for decades: they have higher rates of premature CAD despite **lower LDL-C values than other ethnic groups at the time of their first MI**. JACC Advances data from the INTERHEART study confirmed that South Asians had

mean LDL-C of 125.2 mg/dL at first MI, compared to 150.4 mg/dL for all other Southeast Asian subgroups. The conventional lipid panel — the test every Indian cardiologist orders — is systematically less informative for Indian patients than for their Western counterparts.

The explanations are now well-established. Indians carry **small, dense LDL particles in higher concentrations** — the type counted by ApoB but invisible to LDL-C. They carry elevated Lp(a) in 25% of cases — a genetically determined cardiovascular risk factor with no dietary treatment and no statin response. They have structurally higher hsCRP, reflecting the chronic vascular inflammation that makes the arterial environment more permissive to plaque formation. A standard lipid panel, run on an Indian patient, reads "normal" while the arterial wall is already silently narrowing. → Lancet Regional Health SE Asia, 2023

> 📋 PREMATURE CAD IN INDIANS – PMC REVIEW · PMC1993956
>
> **"Of particular concern to India is not only the high burden of CVDs, but also the effects of these diseases on the productive workforce aged 35–65 years. Heart diseases are rising in Asian Indians 5–10 years earlier than in other populations around the world."**
>
> The mean age for first presentation of acute MI in Indians is 53 years. Prevention strategies must begin not at 50, but at 30 — before the atherogenic process is established. → PMC1993956

THE NCRB DATA: A RISING EMERGENCY

The National Crime Records Bureau (NCRB) — which tracks sudden/unnatural deaths — reported a **12.5% rise in heart attack deaths in 2022 alone, leading to 32,457 recorded deaths**. This figure almost certainly undercounts cardiac mortality, since many deaths attributed to other causes involve undiagnosed CAD. In 2020, heart attacks claimed 19,238 individuals aged 30–60. In 2021, 2,541 deaths were recorded among those aged just 18–30. → PMC12060909

Gujarat saw a 55% increase in heart-related emergency calls in 2023 compared to the previous year — 66,397 calls from January to June alone, per EMRI data. Whether this reflects a true increase in events, improved reporting, or post-COVID

cardiac sequelae remains debated. The trend is unmistakable. The surge is real.

> LANCET — CVD BURDEN CHARACTERISATION, INDIA, 2023
>
> The Lancet Regional Health study published February 2023 characterised the Indian CVD epidemic as having four defining features: **higher relative risk burden · earlier age of onset · higher case fatality · higher premature deaths** — all compared to global averages. "The burden due to CVD in India is remarkably higher than what is being experienced at a global level." → PMC10305862

WHAT THIS DEMANDS OF CLINICIANS

A 2026 review in Springer Nature Clinical & Translational Metabolism described the Indian CAD paradox explicitly: **"accelerated atherosclerosis despite comparatively modest elevations in traditional lipid markers."** The mechanistic pathway involves refined carbohydrate diets, trans fat exposure, micronutrient deficiencies, insulin resistance, and dyslipidaemia — interacting with genetic susceptibility to produce accelerated plaque at LDL levels that would reassure a Western clinician.

The clinical implication is direct: Indian patients presenting for cardiovascular risk assessment need ApoB, Lp(a), fasting insulin, HOMA-IR, and hsCRP — not just a standard lipid panel. These are not exotic tests. They are available. They are not ordered. The gap between what evidence demands and what Indian clinical practice delivers is measured in heart attacks per year. → Springer CTM, 2026

▲ THE MISSING BIOMARKERS

Standard lipid panels miss the key Indian CVD drivers:

ApoB (true particle count)	Rarely ordered
Lp(a) (genetic risk)	Almost never
hsCRP (inflammation)	Rarely ordered
Fasting insulin	Almost never

◆ THE LP(A) NUMBER

25% of Indians carry Lp(a) ≥50 mg/dL — the threshold of significant cardiovascular risk. This is genetic. Statins don't lower it. Diet barely affects it. It is tested once in a lifetime. Almost no Indian ever has it tested.

IV CHAPTER

NCRP · ICMR-NCDIR · INDIAN JOURNAL OF MEDICAL RESEARCH · 2022–2025

Cancer in India 2026

29.8 million DALYs projected for 2025. Rising breast, persistent oral, declining cervical, and the geography of risk

India's cancer burden is characterised by a paradox that defines much of its public health challenge: the country simultaneously suffers from cancers of poverty (cervical, oral, oesophageal — driven by infection, tobacco, and lack of screening) and cancers of affluence (breast, colon, lung — rising with urbanisation and dietary transition). The two epidemics overlap geographically, creating an almost impossible simultaneous demand on health systems that are not adequately equipped for either.

1.46M 29.8M <22% 12LK

1.40M	29.6M	~33%	12.1K
NEW CANCER CASES ESTIMATED, INDIA 2022 (NCRP)	CANCER DALYS PROJECTED FOR 2025 (ICMR-NCDIR)	PROPORTION PRESENTING AT EARLY STAGE FOR COMMON CANCERS	HPV-RELATED CANCERS PROJECTED 2025 (NCRP)

THE FIVE LEADING CAUSES — BY DALY BURDEN

The ICMR-NCDIR burden analysis, published in BMC Cancer (2022) and updated for 2025 projections, identified the seven leading cancer sites contributing over 40% of total cancer DALY burden: lung (10.6%), breast (10.5%), oesophagus (5.8%), mouth (5.7%), stomach (5.2%), liver (4.6%), and cervix uteri (4.3%). → PMC9092762

▲ CANCER DALY CONTRIBUTION BY SITE — INDIA 2021 (ICMR-NCDIR)

Lung	10.6%
Breast	10.5%
Oesophagus	5.8%
Mouth / Oral	5.7%
Stomach	5.2%
Liver	4.6%
Cervix uteri	4.3%

Source: ICMR-NCDIR / BMC Cancer 2022. DALYs = YLLs + YLDs. Projections 2021.

THE CERVICAL-BREAST TRANSITION

The most significant trend in Indian cancer epidemiology over the past decade is the simultaneous decline in cervical cancer incidence and rise in breast cancer incidence — confirmed by the NCRP 2023 report. Cervical cancer, historically India's most common female cancer, has been falling in most registries, likely due to some improvement in awareness and hysterectomy rates. **Breast cancer has now surpassed it to become the leading female cancer by incidence** in urban and

many peri-urban registries.

This transition mirrors the pattern seen in developed countries as they urbanised. The breast cancer rise is driven by later age of first pregnancy, lower breastfeeding rates, increasing obesity, and exposure to endocrine-disrupting lifestyle factors. It is, in a literal sense, a cancer of modernisation. The NCRP data confirm that Delhi, the most urbanised of the major registry cities, is showing a rising trend in overall cancer incidence while most other cities show stability. → Indian J Surg Oncol, 2025

THE HPV OPPORTUNITY

The National Cancer Registry Programme's HPV analysis provides both alarming and optimistic data. Among all Indian cancers, 7.5% are HPV-related. Cervical cancer accounts for 87.6% of HPV-related cancers in women; oropharyngeal cancer accounts for 63.2% in men. **The projected incidence of HPV-related cancers will reach 121,302 by 2025**. Nearly all of these are preventable by vaccination and most are detectable by screening before they become invasive. India's HPV vaccination rollout — launched nationally in 2023 for girls aged 9–14 — represents the most significant single-intervention opportunity to reduce cancer burden in a generation. → PMC9666279

> ⚠ THE STAGE-AT-PRESENTATION CRISIS
>
> Fewer than 33% of patients presenting with common cancers in India do so at an early (Stage I–II) stage. Most present at Stage III or IV, when curative options are limited and five-year survival rates fall sharply. This is not a reflection of cancer biology — it is a failure of awareness, screening infrastructure, and primary care. Breast cancer caught at Stage I has a 5-year survival above 90%. Caught at Stage IV, it falls below 30%. The gap between those numbers is an infrastructure investment that has not been made. → JCO Global Oncology · NCRP

THE REGIONAL HETEROGENEITY

India's cancer geography is strikingly diverse. Age-adjusted incidence rates for males range from 39.5 per 100,000 in Osmanabad-Beed (low tobacco, low urbanisation)

to 269.4 in Aizawl district, Mizoram (high rates of tobacco, dietary factors, and specific genetic susceptibilities). The Northeast — particularly Mizoram, Manipur, Nagaland — carries the highest overall cancer incidence in India for both sexes, driven by high rates of tobacco chewing, smoked tobacco, traditional fermented foods linked to stomach and oesophageal cancer risk, and Helicobacter pylori prevalence.

▲ CANCER INCIDENCE (INDIA 2022 ESTIMATES)

Total new cases (2022)	~1.46M
Leading: Male	Lung, Mouth
Leading: Female	Breast, Cervix
HPV cancers by 2025	121,302
DALYs, 2025 projection	29.8M

◆ THE HPV OPPORTUNITY

India's national HPV vaccination programme (2023 launch) targets girls 9–14. If achieved at 70%+ coverage: estimated **prevention of 60,000–80,000 cervical cancer cases per year** over the next two decades.

This is the single highest-return cancer prevention investment available to India today.

V CHAPTER

AQLI 2025 · GBD 2019 · LANCET PLANETARY HEALTH · FRONTIERS PH

The Air We Breathe

5.3 years of average Indian life. 8.2 years in Delhi. 1.67 million deaths in 2019. What the biology says — and what realistically helps

No single environmental factor shortens more Indian lives than the air. The Air Quality Life Index, published annually by the Energy Policy Institute at the University of Chicago, is derived from peer-reviewed causal research and satellite-measured PM2.5 data. Its 2025 edition calculates that the average Indian loses approximately 5.3 years of life expectancy to particulate pollution — more than twice the loss from malnutrition, more than three times the loss from tobacco. For the 544 million residents of the Indo-Gangetic Plain, the figure exceeds 7 years.

5.3 AVERAGE YRS LOST · INDIA (AQLI 2025)	8.2 YRS LOST · DELHI (AQLI 2025)	9.5 YRS LOST · LUCKNOW (AQLI 2025)	1.67M DEATHS/YR ATTRIBUTED TO POLLUTION (GBD 2019)
17.8% OF ALL INDIAN DEATHS – POLLUTION-ATTRIBUTED	$36.8B ANNUAL ECONOMIC COST (GBD, LANCET PH 2020)		

THE BIOLOGY OF PM2.5

PM2.5 — particles of 2.5 micrometres or less — bypass nasal filtration and deposit in alveolar lung tissue, entering the bloodstream directly. In the bloodstream, they drive oxidative stress and systemic vascular inflammation, accelerating atherosclerosis, triggering arrhythmias, and — via the olfactory nerve — crossing the

blood-brain barrier. A meta-analysis of long-term PM2.5 exposure in LMICs (Frontiers in Public Health, 2023) found cardiovascular morbidity RR 1.11, cardiovascular mortality RR 1.10, and respiratory mortality RR 1.31 per unit PM2.5 increment. → Frontiers PH 2023

For children, maternal PM2.5 exposure during pregnancy impairs fetal lung development in utero — the fetus lacks antioxidant defences and is uniquely vulnerable to oxidative stress during embryonic phases. Children born in high-pollution environments face subclinical respiratory compromise from birth, reduced lung function capacity by adolescence, and higher lifetime rates of COPD, asthma, and cardiovascular disease. India's pollution crisis is intergenerational. → PMC6315719

THE GBD ECONOMIC VERDICT

The Global Burden of Disease Study 2019, published in the Lancet Planetary Health (December 2020), confirmed 1.67 million deaths attributable to air pollution in India — 0.98 million from ambient PM2.5 and 0.61 million from household air pollution. The ambient PM2.5 death rate increased by 115.3% from 1990 to 2019, while household air pollution deaths fell 64.2% as cleaner cooking fuels spread. Economic losses totalled $36.8 billion annually — 1.36% of GDP — with the highest proportional burden falling on the poorest states: UP, Bihar, Rajasthan, MP, Chhattisgarh. → PMC7805008 / Lancet PH

WHAT ACTUALLY WORKS — RANKED BY EVIDENCE

INTERVENTION	EVIDENCE QUALITY	MECHANISM	LIMITATION
HEPA air purifier (bedroom priority)	Strong RCT evidence	Reduces indoor PM2.5; ~3 mmHg systolic BP drop documented	Cannot reach WHO limits in high-ambient environments
N95 respirator (well-fitted)	Strong — multiple RCTs	Reduces inhaled PM2.5; cardiopulmonary marker improvement	Fit is critical; surgical masks do not work for PM2.5

Eliminate biomass cooking	**Strong evidence**	Removes highest-density indoor exposure source	Ujjwala gaps; LPG cost
Timing outdoor exposure	**Moderate (physics sound)**	Avoid 6–9 AM / 7–10 PM peak inversion windows	No hard outcome RCT
Indoor plants for PM2.5	**No PM2.5 evidence**	No mechanism for particulate removal at scale	False reassurance risk

▲ WHO VS INDIA REALITY

WHO annual PM2.5 limit	5 µg/m³
India's national standard	40 µg/m³
Delhi winter peak	200–500+
% Indians exceeding WHO limit	100%

◆ NCAP TARGET

India's National Clean Air Programme targets **20–30% PM2.5 reduction by 2024** in 122 cities. If achieved and sustained: average Indian gains **1.3 years of life expectancy**. IGP residents gain ~2 years.

Even ambitious policy will leave 2050 Indian air ~3× the WHO limit, per modelling.

VI CHAPTER

INDIAN JOURNAL OF MEDICAL RESEARCH · PMC · SAMPLE REGISTRATION SYSTEM · 2021–2025

The Long-Lived

Kerala's 76-year life expectancy, the Northeast paradox, and the social determinants that matter most

---

If the first five chapters of this report document what is going wrong with the Indian body, this one documents what going right looks like — and where.

Kerala stands as the most studied example of a low-income population achieving high-income health outcomes through social investment rather than per-capita GDP. Its life expectancy of approximately 76 years rivals that of many OECD countries. Uttar Pradesh, roughly the same latitude and also Indian, records a life expectancy of approximately 65 years. The gap is not genetic. It is architectural.

KERALA LIFE EXPECTANCY

~76 yr

Rivals many developed nations. Achieved without high per-capita GDP.

INDIA AVERAGE

~68 yr

National average. Wide state-level variance.

UTTAR PRADESH

~65 yr

KERALA FEMALE LITERACY

93.9%

Among the lowest in India. Higher pollution, lower literacy, weaker PHC.

Highest in India. Directly linked to health outcomes.

THE KERALA MODEL — WHAT THE EVIDENCE SHOWS

The "Kerala Model" has been debated and studied by development economists for five decades. Kerala achieved low mortality despite low per capita income — a paradox that contradicted the conventional wisdom that economic growth was a prerequisite for health improvement. The evidence now points to six intersecting factors: → PMC4028815

FACTOR	KERALA STATUS	MECHANISM	EVIDENCE
Female literacy	**93.9% — highest in India**	Educated mothers make better health decisions; lower IMR; better nutrition	Strong correlation across states
Primary healthcare density	**Exceptional PHC network since 1956**	Early detection, management of infectious disease; ante/postnatal care	State intervention credited by multiple analyses
Women's empowerment	**High autonomy, property rights, political participation**	Household health decisions dominated by women → better child outcomes	Consistently cited in Kerala demographic studies
Lower infant mortality	**IMR among lowest in India**	Life-table improvements: lower IMR → higher LE at all ages	SRS data confirms consistently
Social cohesion	**Extended family networks; community**	Reduced chronic stress; mental health support; elder care	Observed association, causal

	support systems		pathway plausible
Geography/climate	Coastal; moderate climate	Seafood access (DHA, omega-3); lower extreme weather events	Contributory, not primary

Critically, the Kerala model has a shadow. Kerala's **morbidity rates — the proportion of people living with illness** — are among the highest in India. Keralites live longer, but they also report more chronic disease in later life, partly because they survive conditions that kill people in other states earlier. The "Kerala paradox" of high life expectancy with high morbidity reflects a health system that keeps people alive but has not yet optimised for quality of life in later years. → GIPE Study, 2023

THE NORTHEAST: A DIFFERENT KIND OF LONGEVITY

Northeast India presents a different and more complicated picture. Life expectancy in the region is generally above the national average for women, driven by high female agency, lower rates of patriarchal health-compromise, and different dietary patterns. However, the Northeast also carries the highest cancer incidence rates in India — particularly for oesophagus, stomach, and nasopharynx cancers — driven by dietary (fermented/smoked foods, betel nut) and tobacco habits that intersect with genetic susceptibilities.

The Northeast's lesson is that longevity and cancer burden can coexist — and that survival statistics, when disaggregated, reveal different risks in different populations. A health policy that treats "the Northeast" as a single entity misses the within-region variation between Mizoram's very high cancer incidence and Sikkim's relatively better oncological outcomes.

> ✓ WHAT CAN BE REPLICATED FROM KERALA
>
> **Universal Primary Healthcare:** Kerala's dense PHC network, built since the 1970s, provides the foundation for early detection, vaccination, and chronic disease management. Investment in sub-centre infrastructure in the poorest states would replicate the structural advantage.

Girls' Education as Health Policy: The single strongest correlate of infant mortality reduction globally is female literacy. Kerala's educational investment preceded its demographic transition by one generation. States investing in girls' education now will see the health dividend in 20 years.

Women's Empowerment in Health Decisions: The evidence is consistent across multiple analyses: households where women have decision-making authority over nutrition, healthcare-seeking, and family size produce better child health outcomes at every income level.

▲ LIFE EXPECTANCY AT BIRTH – INDIA

Kerala (highest)	~76 yr
Tamil Nadu	~73 yr
India Average	~68 yr
UP / MP (lowest bracket)	65–67 yr

◆ THE 11-YEAR GAP

Kerala's life expectancy exceeds UP's by approximately **11 years**. This is not biological. It is the accumulated effect of primary healthcare investment, female literacy, and social infrastructure built over 60 years. It can be built elsewhere — but not quickly.

VII CHAPTER

GBD 2021 PROJECTIONS · IHME · WEF · WHO SDG TRACKING · 2023–2025

The 2050 Roadmap

What the projections show, where the inflection points are, and what decisions made now will determine the India of 2050

The India of 2050 is already determined — in its broad outlines — by the biology that is developing in Indian bodies today. Chronic diseases take 20–30 years to manifest as mortality. The insulin resistance forming in a 25-year-old Mumbai professional today will, if unchecked, produce a heart attack or kidney failure by 2045. The arterial damage accumulating in a 10-year-old breathing Lucknow's winter air is being laid down now. The cancer in a 30-year-old woman who has never had a cervical smear will be diagnosed — if it is diagnosed — at Stage III, in 2040, when curative options are limited. The 2050 roadmap is not a forecast. It is a consequence.

THE POPULATION AGEING MULTIPLIER

India's demographic transition is accelerating the NCD crisis. The proportion of India's population over 50 — currently approximately 16% — is projected to reach **33% by 2050**. India's aging population is expected to reach 340 million by 2050. Within the next two decades, older adults will bear nearly half of the total disease burden, mostly from NCDs. → PMC3842902

The intersection of an ageing population with the metabolic disease cohort now being created — the 101 million diabetics, the 136 million in prediabetes, the 315 million hypertensives — means that India in 2030–2050 will face an NCD burden at a scale and pace that its healthcare system is structurally unprepared to handle. The WEF estimated India stands to lose **$4.58 trillion before 2030 due to NCDs and mental health conditions** — cardiovascular disease accounting for $2.17 trillion of that figure. → WEF Economic Report

340M	33%	$4.58T	55%
PROJECTED INDIAN ELDERLY POPULATION BY 2050	POPULATION OVER 50 BY 2050 (FROM 16% TODAY)	PROJECTED NCD ECONOMIC LOSS BY 2030 (WEF)	DALYS FROM NCDS IN 2016 (UP FROM 30% IN 1990)

THE INFLECTION POINTS — WHERE INTERVENTION CHANGES TRAJECTORY

INFLECTION 01 – THE METABOLIC WINDOW (AGE 25–35)

The decade between 25 and 35 is when insulin resistance, visceral fat accumulation, and early arterial atherogenesis are most reversible in Indians. Diet, exercise, and targeted supplementation (Vitamin D, B12, correction of iron status) at this stage prevent decades of organ damage. The annual metabolic panel described in this report — ApoB, Lp(a), HOMA-IR, hsCRP, ferritin, B12, Vitamin D, HbA1c, fasting insulin — costs ₹2,000 and represents the highest-return health investment a 30-year-old Indian can make. **Universal metabolic screening from age 25 would be one of the most cost-effective public health interventions in Indian history.**

INFLECTION 02 – HPV VACCINATION COVERAGE (NOW–2030)

India's HPV vaccination programme — launched in 2023, targeting girls 9–14 — will determine cervical cancer rates in the 2050s. The NCRP projects 121,302 HPV-related cancer cases annually by 2025. With 70%+ vaccination coverage, the long-term prevention potential is 60,000–80,000 cases per year. The window for intervention is the pre-sexual debut period. **Every year of vaccination programme delay is 60,000 cancers unpreventable.**

INFLECTION 03 – AIR QUALITY AND THE IGP (NOW–2035)

The NCAP target of 20–30% PM2.5 reduction, if sustained, yields 1.3 years of average life expectancy gained and approximately 2 years for IGP residents. Ambitious policy (large-scale shift from biomass and coal) could reduce excess mortality by 23.6% — 775,000 deaths avoided annually by 2030. Even under the most optimistic scenario, India's 2050 air will remain 3× the WHO guideline. The opportunity for intervention is now, in the policy decisions of the current decade.

Delay compounds linearly. → PMC7935015

INFLECTION 04 — THE PRIMARY HEALTHCARE INFRASTRUCTURE GAP

The GBD study tracking progress toward WHO NCD targets found India on course to meet chronic respiratory disease targets, but significantly off-track for cardiovascular disease, diabetes, and cancer mortality reduction. The India Hypertension Control Initiative and NP-NCD programmes provide frameworks — but require **"stronger political will, effective implementation, and adequate financing at state level"** to deliver at population scale. The Kerala model demonstrates that primary healthcare infrastructure is the single most replicable intervention available. The question is investment scale and timeline. → Wiley SD 2023

"The epidemic of chronic disease in India is not a forecasting problem. It is a decision problem. The trajectory is already set by the biology now forming in Indian bodies. What can be changed is the magnitude of the consequence — and that window is open for perhaps another decade."

— EDITORIAL SYNTHESIS · THE STATE OF THE INDIAN BODY, VOL. 01, 2026

THE 2050 SCENARIOS

SCENARIO	ASSUMPTIONS	NCD MORTALITY BY 2050	LIFE EXPECTANCY GAIN
Business as Usual	Current policy pace; no major diet/lifestyle shift	**Continues to rise sharply**	**Minimal (~1 yr)**
Moderate Intervention	NCAP + INDIAB-informed screening + HPV rollout	**Stabilises by 2040**	**+2–3 yr average**
Ambitious Intervention	Universal screening · Air quality control · PHC investment · Tobacco elimination ·	**Declining from**	**+5–7 yr by 2050**

	HPV vaccination	2035	

The difference between the Business as Usual and Ambitious scenarios, extrapolated across 1.4 billion people, represents hundreds of millions of life-years. The interventions required are known. The evidence base is established. What remains is the will to implement — in clinical practice, in public policy, and in the conversations that citizens have with their own bodies, their own doctors, and their own governments. This report exists to make those conversations more informed.

▲ THE 4 INFLECTION POINTS

01 · Metabolic screening from age 25	Now
02 · HPV vaccination 70%+ coverage	By 2030
03 · NCAP air quality targets met	By 2030
04 · PHC investment at Kerala scale	2025–2040

◆ WHAT VOL. 02 WILL COVER

Mental health burden — India has 197 million with mental health disorders, the largest absolute number globally. The treatment gap exceeds 80%.

Antibiotic resistance — India is the world's largest consumer of antibiotics and faces a mounting resistance crisis.

Maternal mortality — state-level variation and what drives the North-South divide.

Full Citations & Sources

● ALL SOURCES PEER-REVIEWED, INDEXED, OR PUBLISHED BY NAMED INSTITUTIONS · VERIFIED MAY 2026

1 ICMR-INDIAB-17. Anjana RM et al. *Lancet Diabetes & Endocrinology*, 2023. doi:S2213-8587(23)00119-5

2 AQLI 2025 Report, EPIC University of Chicago. aqli.epic.uchicago.edu

3 GBD 2019 — Air Pollution in States of India. *Lancet Planetary Health*, 2020. PMC7805008

4 Indian Heart Association — Premature MI Statistics. *PMC*, 2024. PMC12060909

5 Lancet — CVD Epidemic in Indians. *Lancet Reg Health SE Asia*, 2023. PMC10305862

6 Premature CAD Review. *PMC*. PMC1993956

7 NCRP Cancer Burden 2021–2025. *BMC Cancer*, 2022. PMC9092762

8 NCRP Cancer Incidence 2022, Projections 2025. *IJMR*, 2022. IJMR 2022

9 HPV-Related Cancers India. NCRP. *PMC*. PMC9666279

10 NCRP Statistics 2020. *JCO Global Oncology*. doi:GO.20.00122

11 Kerala Longevity / Mortality. *PMC*. PMC4028815

12 Socioeconomic Factors & Longevity, Kerala. *Indian J Med Res*. PMC3121277

13 Life Expectancy vs Healthy Life Years, India States. GIPE, 2023. gipe.ac.in

14 Hyperinsulinaemia as Early Biomarker. *Frontiers CDHE*, 2023. PMC10186728

15 Asian Indian Prediabetes Study. ClinicalTrials. NCT04507685

16 HbA1c + FPG Screening, Kerala Youth. *PMC*, 2025. PMC12274043

17 HEPA / N95 Interventions Review. *Curr Environ Health Rep*, 2020. PMC7749091

18 PM2.5 CV & Respiratory Disease LMICs. *Frontiers PH*, 2023. Frontiers 1134341

19 Maternal Air Pollution & Child Lung Health. *PMC*. PMC6315719

20 India Air Quality Capacity Building. *PMC*. PMC7553192

21 NCD Projections to 2050 (GBD 2021). *PMC*. PMC12694828

22 India's NCD Burden & SDG Tracking. *Wiley Sustainable Dev*, 2023. doi:sd.2761

23 Early Onset CAD Paradox. *Springer CTM*, 2026. Springer 2026

24 WEF — Economics of NCDs in India. World Economic Forum, 2014. WEF Report

THE STATE OF THE INDIAN BODY

VOL. 01 · ANNUAL REPORT · 2026

This report synthesises peer-reviewed clinical research, indexed journal publications, and publicly available epidemiological data. Every claim is attributed to a named source. It does not constitute medical advice. All cited studies are linked for independent verification. Vol. 02 will be published May 2027 and will cover mental health, antibiotic resistance, maternal mortality, and the emerging oncology treatment gap. This document is dedicated to the next generation of Indian clinicians, journalists, policy-makers, and citizens who deserve to know — in one place, citation-grade — how the country's bodies are actually doing.